logo
Share SHARE
FONT-SIZE Plus   Neg

Valeant Pharma, Actavis In Merger Talks : WSJ

Canadian drugmaker Valeant Pharmaceuticals International, Inc. (VRX,VRX.TO) is said to be in discussions to acquire rival Actavis Inc. (ACT) for over $13 billion, according to the Wall Street Journal.

While the companies were working towards an all-stock deal announcement, few Actavis' directors were against it around the middle of this week. But the executives on both sides are still working to resurrect the deal, the journal added.

In February, Valeant announced that it was in talks to make more acquisitions, and it remains open to discuss a potential "merger of equals". Actavis currently has a market value of nearly $13 billion.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Facebook (FB) announced Thursday it has agreed to release advertisements purchased by Russians in an effort to influence last year's election to congressional investigators. Calling North Korean nuclear weapons and missile development a grave threat to global peace and security, President Donald Trump announced Thursday he has signed an executive order seeking to crack down on trade with the reclusive communist nation. Come weekends and the ride sharing company Lyft in association with the beer brand Budweiser will offer free travel for short distances. The program is aimed at discouraging drunk driving on holidays. The offer of 150,000 free trips will be available in 10 states, all through the year.
comments powered by Disqus
Follow RTT